Physician profile
Amir Azadi
NPI 1154615607
$24,955.22
in general payments reported to CMS, 2019-2025
37 companies · $1,443 in 2025
The $1,443 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $506 · 2020: $1,311 · 2021: $430 · 2022: $1,839 · 2023: $13K · 2024: $6,837 · 2025: $1,443.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Food and Beverage: $5,493 · Travel and Lodging: $1,000 · Education: $126.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,250.00 |
| Food and Beverage | $5,493.10 |
| Travel and Lodging | $1,000.00 |
| Education | $125.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $11,377.89 | 2022-2023 | Tukysa, Adcetris |
| Pfizer INC. | $3,625.13 | 2023-2025 | |
| Novocure INC. | $2,010.21 | 2019-2025 | Optune, Optune Gio, Optune Lua (Novottf-200t) |
| Gt Medical Technologies, INC | $1,775.99 | 2024 | Gammatile |
| Monteris Medical Corporation | $1,669.92 | 2022-2025 | Neuroblate |
| Bayer Healthcare Pharmaceuticals INC. | $1,164.61 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $352.09 | 2023-2025 | Enhertu, Imfinzi |
| Abbvie INC. | $278.20 | 2023-2025 | Venclexta |
| E.R. Squibb & Sons, L.L.C. | $253.11 | 2021-2024 | Opdivo |
| Astellas Pharma US INC | $217.20 | 2023-2025 | Padcev |
| Daiichi Sankyo INC. | $211.95 | 2023-2025 | Enhertu |
| Intuitive Surgical, INC. | $195.68 | 2022-2025 | |
| Gilead Sciences, INC. | $172.08 | 2023-2024 | Trodelvy |
| Stemline Therapeutics INC. | $150.24 | 2024-2025 | Orserdu |
| Telix Pharmaceuticals | $141.24 | 2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $141.06 | 2022 | |
| Springworks Therapeutics, INC. | $121.76 | 2025 | Gomekli |
| Alexion Pharmaceuticals, INC. | $120.82 | 2019 | |
| Novartis Pharmaceuticals Corporation | $117.19 | 2023-2025 | |
| Portola Pharmaceuticals, LLC | $115.90 | 2020 | |
| Icotec Medical INC. | $104.33 | 2023 | Icotec Blackarmor Spine System |
| Caris Mpi, INC. | $90.60 | 2025 | Mi Cancer Seek |
| Janssen Pharmaceuticals, INC | $90.00 | 2020 | |
| Progenics Pharmaceuticals, INC. | $74.32 | 2022-2023 | Pylarify |
| Menarini Silicon Biosystems, INC. | $68.13 | 2024 | |
| Sobi, INC | $55.80 | 2023 | |
| Eisai INC. | $52.97 | 2024-2025 | |
| Janssen Biotech, INC. | $39.08 | 2022-2023 | Erleada |
| Beone Medicines USA, INC. | $30.23 | 2025 | Tevimbra |
| Jazz Pharmaceuticals INC. | $28.94 | 2025 | |
| Pharmacyclics LLC, An Abbvie Company | $24.08 | 2023 | Imbruvica |
| Beigene USA, INC. | $23.65 | 2025 | Tevimbra |
| Verity Pharmaceuticals INC. | $22.18 | 2022 | |
| Aspira Women'S Health INC | $20.83 | 2022 | |
| Mirati Therapeutics, INC. | $16.54 | 2024 | Krazati |
| Array Biopharma INC | $1.27 | 2024 | Mektovi, Braftovi, Lorbrena |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amir Azadi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.